Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today's Pharmaceutical Executive Daily, FDA's advisory committee votes in favor of Replimune's RP1 efficacy data in advanced melanoma, three clinical-stage biopharmaceutical companies file for IPOs spanning cardiovascular, immune, and metabolic disease, and a new analysis examines why two-thirds of pharmaceutical product launches fail to meet expectations. Attovia Therapeutics is offering shares in the same price range to advance its interleukin-31 targeting candidate for chronic itch conditions, estimating net proceeds of roughly $182 million. And Vogenx is offering shares between $11 and $13 to fund mizagliflozin, an SGLT1 inhibitor for post-bariatric hypoglycemia and gastroparesis. Thanks for listening to Pharmaceutical Executive Daily.